Sarepta Therapeutics (SRPT) Stock Forecast & Price Target $16.80 -0.16 (-0.94%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$16.89 +0.09 (+0.51%) As of 05/22/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Sarepta Therapeutics - Analysts' Recommendations and Stock Price Forecast (2026) How MarketBeat Calculates Price Target and Consensus Rating Consensus Rating HoldBased on 28 Analyst RatingsSell6Hold13Buy9 Based on 28 Wall Street analysts who have issued ratings for Sarepta Therapeutics in the last 12 months, the stock has a consensus rating of "Hold." Out of the 28 analysts, 6 have given a sell rating, 13 have given a hold rating, and 9 have given a buy rating for SRPT. Consensus Price Target $27.1761.75% Upside According to the 28 analysts' twelve-month price targets for Sarepta Therapeutics, the average price target is $27.17. The highest price target for SRPT is $80.00, while the lowest price target for SRPT is $13.00. The average price target represents a forecasted upside of 61.75% from the current price of $16.80. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Get the Latest News and Ratings for SRPT and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Sarepta Therapeutics and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SRPT Analyst Ratings Over TimeTypeCurrent Forecast5/23/25 to 5/23/261 Month Ago4/23/25 to 4/23/263 Months Ago2/22/25 to 2/22/261 Year Ago5/23/24 to 5/23/25Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)1 Strong Buy rating(s)Buy9 Buy rating(s)9 Buy rating(s)9 Buy rating(s)17 Buy rating(s)Hold13 Hold rating(s)13 Hold rating(s)13 Hold rating(s)5 Hold rating(s)Sell6 Sell rating(s)6 Sell rating(s)6 Sell rating(s)0 Sell rating(s)Consensus Price Target$27.17$32.63$33.84$122.61Forecasted Upside61.75% Upside59.79% Upside79.24% Upside223.51% UpsideConsensus RatingHoldHoldHoldModerate Buy SRPT Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History SRPT Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Sarepta Therapeutics Stock vs. The CompetitionTypeSarepta TherapeuticsMedical CompaniesBroader MarketConsensus Rating Score 2.11 2.30 2.52Consensus RatingHoldHoldModerate BuyPredicted Upside61.75% Upside1,714.95% Upside15.09% UpsideNews Sentiment RatingNeutral NewsSee Recent SRPT NewsNeutral NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export DateBrokerageAnalystActionRatingPrice TargetReport Date Upside/DownsideDetails5/8/2026 Weiss RatingsNot Rated UpgradeSell (D) ➝ Sell (D+)4/16/2026 HC Wainwright3 of 5 starsMitchell S.Not RatedReiterated RatingSell4/7/2026 Royal Bank Of Canada3 of 5 stars Boost TargetSector Perform$18.00 ➝ $19.00-17.68%3/26/2026 WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Boost TargetOutperform$29.00 ➝ $35.00+56.71%3/26/2026 Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Boost TargetSell$12.00 ➝ $14.00-37.32%3/26/2026 CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingYigal NochomovitzSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetSell$9.00 ➝ $13.00-40.49%3/26/2026 Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingGil BlumSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingUnderperform3/19/2026 OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingKostas BiliourisSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingOutperform$37.00+117.12%3/12/2026 MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUy EarSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetOutperform$26.00 ➝ $31.00+81.92%3/3/2026 Loop CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingIlya ZubkovSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingSet Target$25.00+57.53% Get the Latest News and Ratings for SRPT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 3/3/2026 Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingAndrew TsaiSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingBuy$30.00+85.87%2/27/2026 Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingYanan ZhuSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetOverweight$45.00 ➝ $38.00+128.13%1/28/2026 BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingGena WangSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingInitiated CoverageEqual Weight$20.00-9.79%11/5/2025 GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDebjit ChattopadhyaySubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetBuy$22.00 ➝ $19.00+3.54%11/4/2025 Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBrian SkorneySubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetNeutral$21.00 ➝ $15.00-38.65%10/30/2025 Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBiren AminSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetNeutral$15.00 ➝ $16.00-31.02%10/22/2025 Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingTazeen AhmadSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetUnderperform$16.00 ➝ $18.00-16.91%9/22/2025 BMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingKostas BiliourisSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$50.00+186.86%9/9/2025 Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingJoseph SchwartzSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetMarket Perform$12.00 ➝ $15.00-15.33%8/7/2025 The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSalveen RichterSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetNeutral$19.00+9.05%7/29/2025 William BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Reiterated RatingOutperform7/29/2025 Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingMatthew HarrisonSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetEqual Weight$15.00 ➝ $20.00+44.30%7/29/2025 Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingWilliam PickeringSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingInitiated CoverageMarket Perform$13.00-6.20%7/29/2025 JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingAnupam RamaSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeUnderweight ➝ Neutral$24.00+73.16%7/21/2025 UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingEliana MerleSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral6/18/2025 TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingRitu BaralSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingDowngradeBuy ➝ Hold$24.00+11.32%6/17/2025 Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingAndy ChenSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingInitiated CoveragePeer Perform6/16/2025 Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingKristen KluskaSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral6/6/2025 ScotiabankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLouis ChenSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeSector Perform ➝ Sector Outperform$80.00+104.03%5/8/2025 EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingGavin Clark-GartnerSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingDowngradeOutperform ➝ Inline$50.00+36.17%10/10/2024 Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDanielle BrillSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingOutperform$150.00+27.61%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 10:27 PM ET. SRPT Forecast - Frequently Asked Questions What is Sarepta Therapeutics' forecast for 2026? According to the research reports of 28 Wall Street equities research analysts, the average twelve-month stock price forecast for Sarepta Therapeutics is $27.17, with a high forecast of $80.00 and a low forecast of $13.00. Should I buy or sell Sarepta Therapeutics stock right now? 28 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sarepta Therapeutics in the last year. There are currently 6 sell ratings, 13 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" SRPT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SRPT, but not buy additional shares or sell existing shares. Does Sarepta Therapeutics's stock price have much upside? According to analysts, Sarepta Therapeutics's stock has a predicted upside of 61.75% based on their 12-month stock forecasts. Has Sarepta Therapeutics been upgraded by Wall Street analysts recently? Over the previous 90 days, Sarepta Therapeutics's stock had 2 upgrades by analysts. What analysts cover Sarepta Therapeutics? Sarepta Therapeutics has been rated by research analysts at Citigroup, Deutsche Bank Aktiengesellschaft, HC Wainwright, Jefferies Financial Group, Loop Capital, Mizuho, Needham & Company LLC, Oppenheimer, Royal Bank Of Canada, Wedbush, Weiss Ratings, and Wells Fargo & Company in the past 90 days. Do Wall Street analysts like Sarepta Therapeutics more than its competitors? Analysts like Sarepta Therapeutics less than other "medical" companies. The consensus rating score for Sarepta Therapeutics is 2.11 while the average consensus rating score for "medical" companies is 2.30. Learn more on how SRPT compares to other companies. Stock Forecasts and Research Tools Related Companies CytomX Therapeutics Stock Forecast Editas Medicine Stock Forecast Qiagen Stock Forecast Kymera Therapeutics Stock Forecast Protagonist Therapeutics Stock Forecast Spyre Therapeutics Stock Forecast Mirum Pharmaceuticals Stock Forecast Rhythm Pharmaceuticals Stock Forecast Lantheus Stock Forecast TG Therapeutics Stock Forecast Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Brokerages With Sarepta Therapeutics RecommendationsWeiss RatingsHC WainwrightRoyal Bank Of CanadaNeedham & Company LLCDeutsche Bank AktiengesellschaftWedbushCitigroupOppenheimerMizuhoJefferies Financial GroupLoop CapitalWall Street ZenWells Fargo & CompanyBarclaysGuggenheim This page (NASDAQ:SRPT) was last updated on 5/23/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredThe AI stocks about to become worthless (and one that isn't)Louis Navellier - who manages $1.1 billion including $358 million in AI stocks - says a new AI computer being ...InvestorPlace | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sarepta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sarepta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
